Technologies and platforms
« Omics » platforms: tumor and host
genomics, study of metabolic pathways,
caracterization of prognostic or diagnostic
markers
Flowcytometry platforms, some of which are
accredited by IBISA, the French National
Infrastructure in Health Biology and Agronomy
Imaging platforms : cellular, tissular, viable
cells, small animal
Platforms for centralized review of pathology
and imaging (PET, CT) in clinical trials
Histopathology lab devoted to lymphoma:
immunohistochemistry, DNA/RNA extraction on
paraffin, tissue microarraying …
Biological sampling logistics platform and
biobanks
LYSARC « data management center»
(accreditation from the French Cancer Institute)
for clinical trials from phase I to phase III-,:
regulatory affairs, monitoring, data
management, biostatistics, pharmacovigilance,
quality assurance…
LYSA network of 130+ clinical investigation
centers including 6 centers accredited « Early
phase clinical trials centers » by the French
National Cancer Institute
Tools for data digitization (electronic case
report form, digital pathology slide scanner,
web-based software for loading and central
review of clinical imaging)
Assets
Animal models
Cell lines
Original collection of viable cells
Biological collections (tissues, plasma,
DNA/RNA)
Proprietary databases
www.instituts-carnot.eu
Institut Carnot CALYM
Centre Hospitalier Lyon-Sud
Secteur Sainte Eugénie
Pavillon 6E
69495 PIERRE-BÉNITE Cedex
France
Pascal DESCHASEAUX
General manager
+33 (0)4 72 66 38 67
pascal.deschaseaux@calym.org
Véronique STANIEK
Director of operations
+33 (0)4 72 66 38 72
veronique.staniek@calym.org
CONTACT
Research personnel
(full-time equivalent):
267
including PhD students:
43
Partnership
research incomes:
15 395 k
€
Global budget:
22 000 k
€
Four R&D pillars
In order to cover all stages
of therapeutic and diagnostic
development - from preclinical
to clinical - and to answer
current unmet medical
needs in the lymphoma
field, CALYM is organized
around four R&D pillars